. Author manuscript; available in PMC: 2021 Jul 30.

Published in final edited form as: Anticancer Res. 2017 Jun;37(6):2831–2838. doi: 10.21873/anticanres.11634

Table I.

Half-maximal inhibitory concentrations for 5-flourouracil (5-FU) and mitogen-activated protein kinase kinase 162 (MEK162) and combination index (CI) for their combination for different human colorectal carcinoma cell lines. Data are the mean±SD.

Cell line	5-FU (μM)	MEK162 (μM)	CI^*
CaCO2 (KRAS/BRAF WT)	23.59±2.18	2.91±0.68	0.46
HCT116 HKE3 (KRAS disrupted allele/BRAF WT)	12.36±2.26	2.54±0.46	2.53
DLD-1 DKO4 (KRAS disrupted allele/BRAF WT)	23.47±4.04	1.99±0.20	1.40
SW480 (KRAS^G12V MT)	84.81±11.91	2.05±0.16	0.13
HCT116 (KRAS^G13D MT)	14.08±1.52	1.71±0.15	0.70
DLD-1 (KRAS^G13DMT)	26.35±3.21	3.99±0.53	0.90

WT, Wild-type; MT, mutant.

Mean values at effective dose of 50%, 0.1-0.3: strong synergism, 0.3-0.7: synergism, and 0.7-0.9: slight synergism.